文献速递慢性肾脏病肾血管病与高血压

尿液和血浆ADMA与糖尿病肾脏病动脉粥样硬化风险的关联:慢性肾功能不全队列(CRIC)研究结果

Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该病例队列研究纳入基线糖尿病且eGFR<60 mL/min/1.73 m²的CRIC参与者,评估血浆及尿ADMA、SDMA、TMAO与动脉粥样硬化性心血管疾病(ASCVD)和心力衰竭的关联。结果显示较高的血浆ADMA和较低的ADMA排泄分数与ASCVD风险相关,而SDMA和TMAO与ASCVD及心力衰竭均无关联。

要点

  • 血浆ADMA每升高1个标准差,ASCVD风险HR为1.30(95%CI 1.01-1.68)。
  • ADMA排泄分数最低四分位组较最高四分位组ASCVD风险HR为2.25(95%CI 1.08-4.69)。
  • 血浆及尿ADMA、SDMA、TMAO均与心力衰竭发生无关联。

核心结论

  • 数据提示肾脏排泄ADMA减少导致血浆ADMA浓度升高,并与ASCVD风险增加相关。

研究设计与样本

  • 病例队列研究,纳入慢性肾功能不全队列(CRIC)中基线糖尿病、eGFR<60 mL/min/1.73 m²且无各结局既往史的参与者,子队列为随机选取符合入组标准者。

主要发现

  • 较高的血浆ADMA浓度(每标准差)与ASCVD风险相关,HR 1.30(95%CI 1.01-1.68)。
  • 较低的ADMA排泄分数(每标准差)与ASCVD风险相关,HR 1.42(95%CI 1.07-1.89)。
  • ADMA排泄分数最低四分位组较最高四分位组ASCVD风险更高,HR 2.25(95%CI 1.08-4.69)。
  • 血浆SDMA、TMAO浓度及排泄分数与ASCVD无关联。
  • 血浆及排泄分数的ADMA、SDMA、TMAO均与心力衰竭发生无关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease (CKD) is associated with atherosclerotic cardiovascular disease (ASCVD) risk, especially among those with diabetes. Altered metabolism of solutes that accumulate in CKD [asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and trimethylamine N-oxide (TMAO)] may reflect pathways linking CKD with ASCVD. METHODS: This case-cohort study included Chronic Renal Insufficiency Cohort participants with baseline diabetes, estimated glomerular filtration rate <60 mL/min/1.73 m2, and without prior history for each outcome. The primary outcome was incident ASCVD (time to first myocardial infarction, stroke or peripheral artery disease event) and secondary outcome was incident heart failure. The subcohort comprised randomly selected participants meeting entry criteria. Plasma and urine ADMA, SDMA and TMAO concentrations were determined by liquid chromatography-tandem mass spectrometry. Associations of uremic solute plasma concentrations and urinary fractional excretions with outcomes were evaluated by weighted multivariable Cox regression models, adjusted for confounding covariables. RESULTS: Higher plasma ADMA concentrations (per standard deviation) were associated with ASCVD risk [hazard ratio (HR) 1.30, 95% confidence interval (CI) 1.01-1.68]. Lower fractional excretion of ADMA (per standard deviation) was associated with ASCVD risk (HR 1.42, 95% CI 1.07-1.89). The lowest quartile of ADMA fractional excretion was associated with greater ASCVD risk (HR 2.25, 95% CI 1.08-4.69) compared with the highest quartile. Plasma SDMA and TMAO concentration and fractional excretion were not associated with ASCVD. Neither plasma nor fractional excretion of ADMA, SDMA and TMAO were associated with incident heart failure. CONCLUSION: These data suggest that decreased kidney excretion of ADMA leads to increased plasma concentrations and ASCVD risk.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Schrauben SJ, Sapa H, Xie D, et al. Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Nephrol Dial Transplant. 2023. PMID: 37230949. doi:10.1093/ndt/gfad103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。